PTC/SB/08s (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patient and Trademark Office; U.S. DEPARTMENT OF COMMERCE to a collection of information unfees of contrars a valid OMB control number.

Remove

U.S. Printer and Trainmank Office, U.S. DEPARTNENT OF COMMERC.

U.S. Printer and Trainmank Office, U.S. DEPARTNENT OF COMMERC.

Under the Paperwork Reduction Act of 1995, no persons we required to respond to exclude on information unless of contains a valid OMS control number.

Application Number

	Application (tulliber			
	Filing Date			
INFORMATION DISCLOSURE	First Named Inventor Pekka		ka Linnonmaa	
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit			
(Notice capillosion and of or the root)	Examiner Name			
	Attorney Docket Numb	er	TAMPPAT-21	

U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date		Name of Patentee of Applicant		Columns,Lines where nt Passages or Releva s Appear	
	1	6401355	B1	2002-06-11	Linnonmaa ei	tal.			
	2	6698342	B1	2004-03-02	Heikkinen et	al.			
	3	6758135	B2	2004-07-06	Linnonmaa e	tal.			
	4	7059066	B2	2006-06-13	Maurer				
If you wis	h to a	dd additional U.S. Pater	t citatio	n information	please click the	Add button.		Add	_
			U.S.P	ATENT APPI	ICATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date		Name of Patentee or Applicant of cited Document		Columns,Lines where nt Passages or Releva s Appear	
	1								
If you wis	h to a	td additional U.S. Publis	shed Ap	plication citat	on information	please click the Ad	d button	Add	_
				FOREIGN PA	ATENT DOCUM	MENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Publication Pate	Name of Patente Applicant of cited Document	e or	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	TK

	1	1 335 066	EP	A1	2003-08-13	Voith Paper Patent GmbH			
	2	01/55504	wo	A1	2001-08-02	Metso Paper, Inc.			
	3	2004/001126	wo	A1	2003-12-31	Metso Paper, Inc.			
	4	2005/088009	wo	A1	2005-09-22	Metso Paper, Inc.			
If you wish to add additional Foreign Patent Document citation information please click the Add button Add									
NON-PATENT LITERATURE DOCUMENTS Remove									
Examiner Initials*	miner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catable, etc), date, pages(s), volume-issue number(s), publisher, city and our country where published.							T5	
International Prelimnary Report on Patentability Issued in PCTIF120050500076									
	2 International Search Report issued in PCT/F/2005.050076								
	3 English Abstract of EP 1 335 966								
If you wish to add additional non-patent literature document citation information please click the Add button Add									
EXAMINER SIGNATURE									
Examiner	Signa	iture				Date Considered			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									

	Application Number		
NEODIA TION DIOCI COURT	Filing Date		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	First Named Inventor Pekk		Linnonmaa
	Art Unit	П	
	Examiner Name		
	Attorney Docket Number		TAMPPAT-21

See first Cooker of USPTO Patient Documents at weer USPTO COOY or METP 9010. If Early office that is used the document, by the locket code (WIPD Assisted STS), 3" Fee pageing early pageing and pageing the pageing of the pageing of

Application Number | Filing Date | Filing Da

CERTIFICATION STATEMENT

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign partie office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart to reign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 155(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(c)(c)

See attached certification statement.

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature		Date (YYYY-MM-DD)	2006-09-07
Name/Drint	David P. I. Stiennon	Registration Number	33212

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant's Office, U.S. operationed for Commence, P. 0. Bot 1450, Alexandria, V.S. 2213.1-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.2313.1-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually intermediate or for extension or about those when the basic high process another examines your submission, which may visually intermediate or for extension or a submission of the basic high process another examines your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pusuant to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandomed or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.